当前位置:首页 > 文献互助 > 互助详情

A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations.复制

用户MiTCsb6qQkVQ 6小时前 10 10 已关闭

DOI: 10.1200/jco.2026.44.7_suppl.161复制

文献链接: https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.161复制

其他信息:

出版社: American Society of Clinical Oncology (ASCO)
作者: Rahul Atul Parikh; Benjamin Herzberg; Mark N. Stein; Shumei Kato; Minal A. Barve; David R. Spigel; Benjamin Garmezy; Alexander Philipovskiy; Gopa Iyer; Alissa Jamie Cooper; Manav Korpal; Maciej Cabanski; Carolina Perdomo Ortiz; Ralph Tiedt; Lisa D. Cleary; Tess Schmalbach; Markus Warmuth; Filip Janku; Alexander I. Spira

互助时间线

2026-05-11 16:08:27 [关闭求助]

系统关闭了求助

备注: 显示free已经是全文了 没有下载选项 直接看网页哦

2026-05-11 12:57:34 [发起求助]